Filing Flows › Regenerative Medical Technology Group (RMTG) › Q2 2026 › vs Q1 2026
Regenerative Medical Technology Group (RMTG) Q2 2026 vs Q1 2026 (quarter over quarter)
Regenerative Medical Technology Group's revenue rose $1.4M (+52%) from $2.6M in Q1 2026 to $4.0M in Q2 2026.
Regenerative Medical Technology Group, Q2 2026: revenue $4.0M (+309% year over year), operating margin 14.1%, net loss $2.9M, operating cash flow $332K. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.2% | -8.1% | +15.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $4.0M | $2.6M | $1.4M | +52% |
| Net loss | $2.9M | $876K | $2.0M | +232% |
| Costs & expenses | $6.9M | $3.5M | $3.4M | +97% |
| Operating costs | $3.5M | $2.4M | $1.0M | +43% |
| Interest & other, net | $3.5M | $1.1M | $2.4M | +214% |
| Cost of revenue | $1.4M | $873K | $572K | +66% |
| Sales & marketing | $547K | $391K | $156K | +40% |
| General & admin | $619K | $476K | $143K | +30% |
| Other operating costs | $846K | $670K | $177K | +26% |
| Operating cash sources | $3.2M | $978K | $2.3M | +231% |
| Depreciation & amortization | $91K | $98K | −$7K | -7% |
| Working capital & other | $3.1M | $881K | $2.3M | +257% |
| Net loss absorbed | $2.9M | $876K | $2.0M | +232% |
| Operating cash flow | $332K | $102K | $230K | +225% |
| Free cash flow (OCF − capex) | $288K | −$213K | $502K | — |
| Capital expenditures | $43K | $315K | −$272K | -86% |
Questions
How much did Regenerative Medical Technology Group's revenue grow quarter over quarter in Q2 2026?
Regenerative Medical Technology Group's revenue rose $1.4M (+52%) from $2.6M in Q1 2026 to $4.0M in Q2 2026.